Format

Send to

Choose Destination
Acta Pharmacol Sin. 2019 Mar 27. doi: 10.1038/s41401-018-0206-4. [Epub ahead of print]

Donepezil, a drug for Alzheimer's disease, promotes oligodendrocyte generation and remyelination.

Cui X1, Guo YE2,3, Fang JH1, Shi CJ1, Suo N2,3, Zhang R4, Xie X5,6,7.

Author information

1
Shanghai Key Laboratory of Signaling and Disease Research, Laboratory of Receptor-based Bio-medicine, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
2
CAS Key Laboratory of Receptor Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
3
University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing, 100049, China.
4
Shanghai Key Laboratory of Signaling and Disease Research, Laboratory of Receptor-based Bio-medicine, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China. ru.zhang@tongji.edu.cn.
5
Shanghai Key Laboratory of Signaling and Disease Research, Laboratory of Receptor-based Bio-medicine, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China. xxie@simm.ac.cn.
6
CAS Key Laboratory of Receptor Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. xxie@simm.ac.cn.
7
Stake Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. xxie@simm.ac.cn.

Abstract

Myelin sheaths play important roles in neuronal functions. In the central nervous system (CNS), the myelin is formed by oligodendrocytes (OLs), which are differentiated from oligodendrocyte precursor cells (OPCs). In CNS demyelinating disorders such as multiple sclerosis (MS), the myelin sheaths are damaged and the remyelination process is hindered. Small molecule drugs that promote OPC to OL differentiation and remyelination may provide a new way to treat these demyelinating diseases. Here we report that donepezil, an acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD), significantly promotes OPC to OL differentiation. Interestingly, other AChEIs, including huperzine A, rivastigmine, and tacrine, have no such effect, indicating that donepezil's effect in promoting OPC differentiation is not dependent on the inhibition of AChE. Donepezil also facilitates the formation of myelin sheaths in OPC-DRG neuron co-culture. More interestingly, donepezil also promotes the repair of the myelin sheaths in vivo and provides significant therapeutic effect in a cuprizone-mediated demyelination animal model. Donepezil is a drug that has been used to treat AD safely for many years; our findings suggest that it might be repurposed to treat CNS demyelinating diseases such as MS by promoting OPC to OL differentiation and remyelination.

KEYWORDS:

CNS demyelinating disorders; aricept; differentiation; donepezil; multiple sclerosis; myelin sheaths; oligodendrocyte; oligodendrocyte progenitor cell; remyelination

PMID:
30918344
DOI:
10.1038/s41401-018-0206-4

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center